Bladder Cancer Weekly

July 06, 2026

Videos

Peer-to-Peer Clinical Conversations

BRAVO Study Examines Cost and Recurrence Outcomes of Blue Light Cystoscopy in NMIBC - Stephen Williams

Stephen Williams

Ashish Kamat speaks with Stephen Williams about the BRAVO study, a propensity-matched retrospective analysis of 311 blue light versus 311 white light cystoscopy patients with NMIBC in the VA Healthcare System from 1997 to 2021.

Investigating Pembrolizumab Alone with Response-Guided Bladder Sparing in MIBC - Matthew Galsky

Matthew Galsky

Matthew Galsky presents HCRN GU 20-444, which enrolled 46 cisplatin-ineligible patients with T2-T3 N0 M0 muscle-invasive bladder cancer receiving two doses of pembrolizumab at six-week intervals.

Beyond the Abstracts

Impact of Asymptomatic Bacteriuria on the Outcomes and Tolerability of Bacillus Calmette-Guérin Immunotherapy - Beyond the Abstract

Population-Based Outcomes of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer in Older Adults - Beyond the Abstract

Conference Coverage

ASCO 2026: Intravesical Recombinant BCG Combined with Chemo-IO as Perioperative Therapy for Patients with MIBC: Primary Analysis of SAKK 06/19

AUA 2026: Debate: Next Generation Markers – Is it Time to Let Go of our Old Friends?

AUA 2026: A Phase 1/2 Study of Intravesical MK-3120 in Participants with Bacillus Calmette-Guérin (BCG)-Naive or BCG-Exposed High-Risk Non–muscle Invasive Bladder Cancer

SES AUA 2026: Response to Treatment with UGN-102 in Patients with Early or Late Recurrent Low-Grade Intermediate Risk NMIBC

EAU 2026: The COBRA Study: Chemoablation or Bladder Resection with Adjuvant Chemotherapy in Recurrent Non Muscle Invasive Bladder Cancer

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

The role of microRNAs-23b and 27b in migration, invasion and proliferation of T24 bladder cancer cells.

Predictors of residual tumour and recurrence in high-grade NMIBC: insights from a multicenter re-TURBT cohort.

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC).

Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.

A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels.

Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease Sites.

Role of Postoperative Radiation Therapy After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.

Impact of Social and Structural Determinants of Health on Bladder Cancer Outcomes: Focus on Non-Muscle-Invasive Disease.

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from the JAVELIN Bladder 100 Trial in Patients with High Body Mass Index or Diabetes Mellitus - Beyond the Abstract

Management of High-Risk Non-Muscle-Invasive Bladder Cancer.

Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBC.

Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer.

State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high-risk non-muscle invasive bladder cancer in the UK (SPAN-UK).

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer.

Invasive urothelial carcinoma in association with surface low-grade papillary urothelial carcinoma: clinical and pathologic insights from a rare entity.

Complete pathological response in patients with bladder cancer: predictors and outcomes.

Perioperative immune-checkpoint inhibitors for muscle-invasive bladder cancer.

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC